Drug Profile
Lobeglitazone - Chong Kun Dang
Alternative Names: CKD-501; Duvie; Lobeglitazone sulfate; M-107Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Developer Aclipse Therapeutics; Chong Kun Dang; EQUIS & ZAROO
- Class Antihyperglycaemics; Gastrokinetics; Pyrimidines; Small molecules; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase I Gastroparesis
Most Recent Events
- 14 Sep 2023 Lobeglitazone licensed to Aclipse Therapeutics worldwide for the treatment of gastroparesis
- 14 Sep 2023 Phase-I clinical trials in Gastroparesis in USA prior to September 2023 (PO) (Aclipse Therapeutics pipeline, September 2023)
- 14 Sep 2023 Aclipse Therapeutics completed a pre-IND meeting with the US FDA for lobeglitazone in gastroparesis prior to September 2023